Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 41

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT04785924Phase 4Withdrawn
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae InfectionGram-Negative Bacterial Infections+1 more
PrincipalinvestigatorStart date: 2021-06-07

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Thirumalaisamy Velavan, PhD

University of Tübingen, Germany

Related
1 trials

Shared therapeutic areas:

Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae Infection
Similarity Score15%

Minh-Dien Tran

National Children's Hospital, Vietnam

Related
1 trials

Shared therapeutic areas:

Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae Infection
Similarity Score15%

Yaovi Mahuton Gildas Hounmanou, PhD

University of Copenhagen

Related
1 trials

Shared therapeutic areas:

Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae Infection
Similarity Score15%

Flavie Goutard, PhD

CIRAD, France

Related
1 trials

Shared therapeutic areas:

Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae Infection
Similarity Score15%

Seetha Shankaran, MD

Wayne State University

Related
49 trials

Shared therapeutic areas:

Gram-Negative Bacterial Infections
Similarity Score8%

Dale L. Phelps, MD

University of Rochester

Related
10 trials

Shared therapeutic areas:

Gram-Negative Bacterial Infections
Similarity Score8%

Brian Potoski, PharmD

University of Pittsburgh

Related
3 trials

Shared therapeutic areas:

Gram-Negative Bacterial Infections

Worked with same sponsors:

Merck Sharp & Dohme LLC
Similarity Score8%

Abhik Das, PhD

RTI International

Related
31 trials

Shared therapeutic areas:

Gram-Negative Bacterial Infections
Similarity Score8%

Michele C. Walsh, MD MS

Case Western Reserve University, Rainbow Babies and Children's Hospital

Related
11 trials

Shared therapeutic areas:

Gram-Negative Bacterial Infections
Similarity Score8%

Juan José Castón Osorio, MD

Hospital General Universitario Reina Sofía de Murcia

Related
2 trials

Shared therapeutic areas:

Carbapenem-Resistant Enterobacteriaceae Infection
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT04785924Phase 4PrincipalInvestigator

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae InfectionGram-Negative Bacterial Infections+1 more
Withdrawn

All 1 trials loaded